Sinopharm Hyundai announced that its wholly-owned subsidiary Sinopharm Group Rongsheng Pharmaceutical Co., Ltd. received the “Drug Registration Certificate” for bumetanib injections approved and issued by the State Drug Administration. Bumetanib injections are mainly suitable for edematous diseases, hypertension, prevention of acute renal failure, hyperkalemia and hypercalcemia, dilute hyponatremia, excessive secretion of antidiuretic hormone, acute drug poisoning, etc.

Zhitongcaijing · 3d ago
Sinopharm Hyundai announced that its wholly-owned subsidiary Sinopharm Group Rongsheng Pharmaceutical Co., Ltd. received the “Drug Registration Certificate” for bumetanib injections approved and issued by the State Drug Administration. Bumetanib injections are mainly suitable for edematous diseases, hypertension, prevention of acute renal failure, hyperkalemia and hypercalcemia, dilute hyponatremia, excessive secretion of antidiuretic hormone, acute drug poisoning, etc.